Press release
Atopic Dermatitis Pipeline Insights Report 2024 | Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd and others.
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Key Takeaways from the Atopic Dermatitis Pipeline Report
• DelveInsight's Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Atopic Dermatitis treatment.
• The leading companies working in the Atopic Dermatitis Market include Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
• Promising Atopic Dermatitis Pipeline Therapies in the various stages of development include Baricitinib, Topical corticosteroid, si-544, Lebrikizumab, MEDI9929, and others.
• March 2024: Eli Lilly and Company announced a study of Phase 3 clinical trials for Baricitinib. The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.
• March 2024: Kymab Limited announced a study of Phase 2 clinical trials for KY1005. A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate-to-Severe Atopic Dermatitis.
Request a sample and discover the recent advances in Atopic Dermatitis Treatment Drugs @ Atopic Dermatitis Pipeline Report- https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Atopic Dermatitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Atopic Dermatitis Overview
Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word 'dermatitis,' 'derm' means 'skin' and 'itis' means 'inflammation.' Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances.
Find out more about Atopic Dermatitis Therapeutics Assessment @ Atopic Dermatitis Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Atopic Dermatitis Emerging Drugs Profile
• Tapinarof: Dermavant Sciences
• Etrasimod: Pfizer
• B244: AOBiome
• Lirentelimab: Allakos Inc.
• QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the Atopic Dermatitis therapies. The Atopic Dermatitis companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. phase III include, Dermavant Sciences.
DelveInsight's Atopic Dermatitis pipeline report covers around 110+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Atopic Dermatitis Pipeline Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Learn more about the emerging Atopic Dermatitis Pipeline Therapies @ Atopic Dermatitis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Atopic Dermatitis Pipeline Report
• Coverage- Global
• Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Atopic Dermatitis Companies- Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
• Atopic Dermatitis Pipeline Therapies- Baricitinib, Topical corticosteroid, si-544, Lebrikizumab, MEDI9929, and others.
Dive deep into rich insights for new drugs for Atopic Dermatitis Treatment, Visit @ Atopic Dermatitis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Atopic Dermatitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Atopic Dermatitis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tapinarof: Dermavant Sciences
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. B244: AOBiome
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. EP262: Escient Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Atopic Dermatitis Key Companies
21. Atopic Dermatitis Key Products
22. Atopic Dermatitis- Unmet Needs
23. Atopic Dermatitis- Market Drivers and Barriers
24. Atopic Dermatitis- Future Perspectives and Conclusion
25. Atopic Dermatitis Analyst Views
26. Atopic Dermatitis Key Companies
27. Appendix
For further information on the Atopic Dermatitis Pipeline therapeutics, reach out to Atopic Dermatitis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://germanydennydones.bloggip.com/profile
https://germanydennydones.creacionblog.com/profile
https://germanydennydones.dm-blog.com/profile
https://germanydennydones.tusblogos.com/profile
https://germanydennydones.spintheblog.com/profile
https://germanydennydones.dailyblogzz.com/profile
https://germanydennydones.bloginder.com/profile
https://germanydennydones.blogvivi.com/profile
https://germanydennydones.bleepblogs.com/profile
https://germanydennydones.get-blogging.com/profile
https://germanydennydones.targetblogs.com/profile
https://germanydennydones.newsbloger.com/profile
https://germanydennydones.blogdal.com/profile
https://germanydennydones.ja-blog.com/profile
https://germanydennydones.blogscribble.com/profile
https://germanydennydones.madmouseblog.com/profile
https://germanydennydones.activoblog.com/profile
https://germanydennydones.blog-ezine.com/profile
https://germanydennydones.blogtov.com/profile
https://germanydennydones.digitollblog.com/profile
https://germanydennydones.blazingblog.com/profile
https://germanydennydones.smblogsites.com/profile
https://germanydennydonesc.weblogco.com/profile
https://germanydennydones.blogdeazar.com/profile
https://germanydennydones.eedblog.com/profile
https://germanydennydones.theisblog.com/profile
https://germanydennydones.blog2freedom.com/profile
https://germanydennydones.qodsblog.com/profile
https://germanydennydones.bloggazza.com/profile
https://germanydennydones.bloggactivo.com/profile
https://germanydennydones.bloggadores.com/profile
https://germanydennydones.blogsvirals.com/profile
https://germanydennydones.blog-gold.com/profile
https://germanydennydones.ambien-blog.com/profile
https://germanydennydones.atualblog.com/profile
https://germanydennydones.blog-a-story.com/profile
https://germanydennydones.blogacep.com/profile
https://germanydennydones.blogadvize.com/profile
https://germanydennydones.bloggerbags.com/profile
https://germanydennydones.bloggerswise.com/profile
https://germanydennydones.bloggosite.com/profile
https://germanydennydones.blogoscience.com/profile
https://germanydennydones.blogproducer.com/profile
https://germanydennydones.blogrelation.com/profile
https://germanydennydones.blogrenanda.com/profile
https://germanydennydones.blogsidea.com/profile
https://germanydennydones.blogthisbiz.com/profile
https://germanydennydones.blue-blogs.com/profile
https://germanydennydones.csublogs.com/profile
https://germanydennydones.dailyhitblog.com/profile
https://germanydennydones.develop-blog.com/profile
https://germanydennydones.livebloggs.com/profile
https://germanydennydones.is-blog.com/profile
https://hyperbookmarks.com/story16829911/atopic-dermatitis-market-size
https://hotbookmarkings.com/story16883941/atopic-dermatitis-market-outlook
https://extrabookmarking.com/story16805585/atopic-dermatitis-market-forecast
https://enrollbookmarks.com/story16793892/atopic-dermatitis-market-trends
https://digibookmarks.com/story16832272/atopic-dermatitis-treatment-market
https://bookmarktune.com/story16785555/atopic-dermatitis-market-insights
https://bookmarkpressure.com/story16812823/atopic-dermatitis-market
https://bookmarkjourney.com/story16864476/atopic-dermatitis-market-size
https://bookmarkindexing.com/story16742365/atopic-dermatitis-market-outlook
https://maximusbookmarks.com/story16970425/atopic-dermatitis-market-forecast
https://bookmarkforest.com/story16794298/atopic-dermatitis-drug-market
https://bookmarkchamp.com/story16807071/atopic-dermatitis-drug-market
https://bookmarkingquest.com/story16806001/atopic-dermatitis-drug-market
https://bookmarkingbay.com/story16763993/atopic-dermatitis-drug-market
https://active-bookmarks.com/story16761273/atopic-dermatitis-market-forecast
https://dmozbookmark.com/story16828056/atopic-dermatitis-drug-market
https://bookmarklinx.com/story16889261/atopic-dermatitis-market-outlook
https://bookmarkerz.com/story16762032/atopic-dermatitis-market-size
https://bookmarkahref.com/story16846516/atopic-dermatitis-drug-market
https://top10bookmark.com/story16738693/atopic-dermatitis-market-size
https://tinybookmarks.com/story16871257/atopic-dermatitis-market-outlook
https://thebookmarknight.com/story16844966/atopic-dermatitis-market-trends
https://scrapbookmarket.com/story16804746/atopic-dermatitis-market-share
https://royalbookmarking.com/story16846844/atopic-dermatitis-drug-market
https://nanobookmarking.com/story16794126/atopic-dermatitis-treatment-market-size
https://modernbookmarks.com/story16676860/atopic-dermatitis-treatment-market
https://listingbookmarks.com/story16875255/atopic-dermatitis-market-trends
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/vulvar-cancer-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Pipeline Insights Report 2024 | Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd and others. here
News-ID: 3434399 • Views: …
More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…

Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…

Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…

Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Atopic
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
Atopic Dermatitis (Atopic Eczema) Treatment Market Business Growth And Industry …
Precision Business Insights published a research report on “Atopic Dermatitis (Atopic Eczema) Treatment Market by Drug type (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Phosphodiesterase type 4 (PDE-4) Inhibitors, Antibiotics, Antihistamines, Emollients), Route of administration (Oral, Topical, Parenteral), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography - Global/Region/Country Forecast to 2027”.
In people who suffer from atopic dermatitis, allergies play a big influence. When the patient is exposed to…